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Abstract
Background: Cancer serum protein profiling by mass spectrometry has uncovered mass profiles
that are potentially diagnostic for several common types of cancer. However, direct mass
spectrometric profiling has a limited dynamic range and difficulties in providing the identification of
the distinctive proteins. We hypothesized that distinctive profiles may result from the differential
expression of relatively abundant serum proteins associated with the host response.
Methods: Eighty-four antibodies, targeting a wide range of serum proteins, were spotted onto
nitrocellulose-coated microscope slides. The abundances of the corresponding proteins were
measured in 80 serum samples, from 24 newly diagnosed subjects with lung cancer, 24 healthy
controls, and 32 subjects with chronic obstructive pulmonary disease (COPD). Two-color rolling-
circle amplification was used to measure protein abundance.
Results: Seven of the 84 antibodies gave a significant difference (p < 0.01) for the lung cancer
patients as compared to healthy controls, as well as compared to COPD patients. Proteins that
exhibited higher abundances in the lung cancer samples relative to the control samples included C-
reactive protein (CRP; a 13.3 fold increase), serum amyloid A (SAA; a 2.0 fold increase), mucin 1
and α-1-antitrypsin (1.4 fold increases). The increased expression levels of CRP and SAA were
validated by Western blot analysis. Leave-one-out cross-validation was used to construct Diagonal
Linear Discriminant Analysis (DLDA) classifiers. At a cutoff where all 56 of the non-tumor samples
were correctly classified, 15/24 lung tumor patient sera were correctly classified.
Conclusion:  Our results suggest that a distinctive serum protein profile involving abundant
proteins may be observed in lung cancer patients relative to healthy subjects or patients with
chronic disease and may have utility as part of strategies for detecting lung cancer.
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Background
Lung cancer remains the leading cause of cancer mortality
in the United States for both men and women [1,2].
Despite significant advances in understanding its biology
and causes, the overall incidence of lung cancer is increas-
ing, and improvements in outcome are not apparent [3].
As treatment is efficacious only for those patients who are
diagnosed sufficiently early in the disease process, a signif-
icant reduction in patient mortality may result from ear-
lier detection of lung cancer, including combinations of
biomarkers with spiral CT imaging [2].
Identification of protein biomarkers in blood or serum
may have utility for noninvasive disease detection and
classification. Biomarker identification would be greatly
enhanced by methodological improvements in protein
detection. Direct serum protein profiling by matrix
assisted laser desorption ionization (MALDI) mass spec-
trometry [4,5] has uncovered distinct mass profiles in sev-
eral common types of cancer. However, the direct
profiling of complex protein mixtures by MALDI has dif-
ficulties in providing the identification of the distinctive
proteins. Further, given the limited dynamic range of
MALDI, it is likely that distinctive features observed in
serum with this approach represent relatively abundant
proteins.
An alternative to mass spectrometry for protein profiling
is the use of antibody microarrays. The field of protein
microarrays currently encompasses applications that
include profiling of serum and tissues from cancer
patients [6,7], autoimmune diagnostics [8], protein inter-
action screening [9-12], as well as antibody-based detec-
tion of multiple antigens [13-17]. Recent increases in
sensitivity and quantitative reproducibility has extended
the utility of antibody microarrays [18,19]. In particular,
direct multicolor labeling with rolling-circle amplification
(RCA) has enabled enhanced sensitivity and reproducible
measurements of low-abundance proteins, as compared
to other direct or indirect labeling detection methods
[20,21]. The strategy behind the two-color RCA detection
is that two different protein samples can be labeled,
respectively, with either biotin or digoxigenin, then both
samples are co-hybridized to the antibody arrays. The
bound proteins are then detected and individually quan-
titated, using RCA (and Cy3) to amplify fluorescence sig-
nals emanating from the bound biotin-labeled proteins,
and RCA (and Cy5) to amplify signals from bound digox-
igenin-labeled proteins. We have previously reported that,
in comparison with either direct or indirect labeling detec-
tion, two-color RCA produced up to 30-fold higher fluo-
rescence intensity measurements, enabling the
reproducible measurements of lower abundance proteins
in serum [20]. Importantly, we have been able to ascertain
reproducible small expression differences between 2 dif-
ferent samples.
In the present study, we have utilized the RCA methodol-
ogy and a panel of 84 antibodies to analyze the relative
abundance of multiple proteins in sera from 24 newly
diagnosed patients with lung cancer, 24 healthy controls,
and 32 patients with chronic obstructive pulmonary dis-
ease (COPD). We have identified a distinctive serum pro-
tein profile for patients with lung cancers.
Methods
Serum samples
Serum samples were obtained following informed con-
sent from 80 individuals, including 24 newly diagnosed
lung cancer patients, 24 healthy subjects without a prior
history of cancer, and 32 patients with COPD. All samples
were collected under protocols approved by the local
Institutional Review Board (IRB). The sera from lung can-
cer patients and healthy controls were collected through
the Early Detection Research Network (EDRN) program at
the University of Michigan. The sera from COPD patients
were collected through the EDRN at New York University.
All samples were stored frozen at -80°C prior to analysis.
Construction of antibody microarrays
The antibodies used in the preparation of the microarrays
were purchased from various sources (a complete list and
further information on each antibody is available online
[22]). The 84 antibodies targeted 80 different proteins,
present at a broad range of concentrations in serum, that
could have levels associated with lung cancer, including
acute phase reactants, proteases and protease inhibitors,
immune system proteins, glycoproteins, extracellular
matrix proteins, and cytokines. Microarray preparation
was performed as described previously [20,23]. Briefly,
samples (20 µl each) of 100–2000 µg/ml antibody solu-
tions in PBS were prepared in polypropylene 384-well
microtiter plates (MJ Research). Small amounts of each
antibody solution were transferred to the surface of nitro-
cellulose-coated microscope slides (PATH slides, Gentel
Biosurfaces) using a piezoelectric non-contact spotter
(Biochip Arrayer, PerkinElmer Life Sciences). Twelve iden-
tical arrays were printed on each of seven slides; each array
consisted of 96 antibodies or control proteins ("baits")
printed in triplicate to form an 18 by 16 array of dots.
Serum labeling
An aliquot (1 µl) from each of 80 serum samples was
labeled with N-hydroxysuccinimide (NHS)-Digoxigenin
(Molecular Probes), and a second aliquot (1 µl) was
labeled with NHS-biotin (Molecular Probes). Each 1 µl
serum aliquot was diluted with 14 µl PBS containing 500
µM NHS-biotin or NHS-Digoxigenin. After the reactions
had proceeded for 1 h on ice, 5 µl of 1 M Tris-HCl (pHBMC Cancer 2005, 5:110 http://www.biomedcentral.com/1471-2407/5/110
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7.5) was added to each tube to quench the reactions, then
the solutions were incubated on ice for an additional 20
min. Non-reactive dye molecules were removed by pass-
ing each solution through a size-exclusion chromatogra-
phy spin column (Bio-Spin P6, Bio-Rad) with a molecular
weight cutoff of 6 kDa. The digoxigenin-labeled samples
were pooled, then distributed equally among the biotin-
labeled samples. 4 µl of Tris-buffered saline (TBS) con-
taining Super Block (Pierce), 1% Brij-35, and 1% Tween-
20 was added to each sample, after which the total volume
of each sample was adjusted to 40 µl with TBS.
Processing of antibody microarrays
Each of the 12 arrays on a slide was circumscribed with a
wax border to segregate the arrays from each other. The
slides were rinsed twice in PBS with 0.5% Tween-20
(PBST0.5) and then blocked 1 h at 4°C in PBS containing
0.1% Tween-20 (PBST0.1), 0.3% CHAPS, and 1% BSA.
After the arrays were briefly rinsed twice with PBST0.5 and
dried by centrifugation, 40 µl of each labeled serum sam-
ple mix was incubated on an array with gentle rocking at
room temp for 1 h. The three groups of samples were
arranged so as to balance the types of samples on each
slide, as shown in a supplementary table. The arrays were
rinsed in PBST0.1, briefly washed three times in PBST0.1,
then dried by centrifugation. Mouse monoclonal anti-
Biotin (Jackson ImmunoResearch) was covalently conju-
gated to a 20-base oligonucleotide (primer 1) as previ-
ously described [20]. Molecular Staging (New Haven, CT)
kindly provided the other reagents necessary for RCA
detection. These included a mouse monoclonal anti-Dig-
oxigenin (Roche) antibody conjugated to a different 20-
base oligonucleotide (primer 4.2), an 81-base circular
DNA (circle 1) with a portion complementary to primer 1,
and an 80-base circular DNA (circle 4.2) with a portion
complementary to primer 4.2. The sequences of the prim-
ers, circles and decorators can be found in the supplemen-
tary information for Zhou et al. [20]. The microarrays
were incubated for 1 h at room temp in PBST0.1 contain-
ing 1 mM EDTA, 5 mg/ml BSA, 75 nM circle 1, 75 nM cir-
cle 4.2, 1.0 µg/ml primer 1-conjugated anti-biotin, and
1.0 µg/ml primer 4.2-conjugated anti-Digoxigenin. The
arrays were rinsed briefly in PBST0.1 then washed at room
temp with gentle rocking three times for 3 min each in
PBST0.1, after which they were incubated in 1X Tango
buffer (Fermentas, Hanover, MD) containing Phi29 DNA
polymerase (New England Biolabs), 0.1% Tween-20 and
0.4 mM dNTPs at 37°C for 30 min. Following a brief rinse
in 2X SSC with 0.1% Tween-20 (SSCT0.1), the arrays were
washed three times for 3 min each at room temperature
with gentle rocking in 2X SSCT0.1, then dried by centrifu-
gation. The arrays were incubated for 1 h (37°C) in 2X
SSCT0.1 containing 0.5 mg/ml herring sperm DNA, Cy3-
labeled 18-bp oligonucleotide complementary to the
repeating DNA strand from primer 1 and a Cy5-labeled
22-bp oligonucleotide complementary to the repeating
DNA strand from primer 4.2, each at 0.1 mM. The arrays
were briefly rinsed in 2X SSCT0.1, washed three times for
3 min each at room temperature in 2X SSCT0.1, dried by
centrifugation, then scanned (ScanArray, PerkinElmer Life
Sciences).
Analysis
The Cy3 and Cy5 fluorescence was quantified using Gene-
Pix software (Axon Instruments). Of the total of 24192
dots, 206 were excluded as having defects by visually
inspecting the images without reference to the quantita-
tive data, with the most common cause of the defect being
overlapping dots. The resultant ".gpr" files for each array
were parsed to create a spreadsheet of the raw data, avail-
able as a supplement [22]. We took the negative of the
base-2 logarithm of the "median of ratios" computed by
the software, and averaged the triplicate measures for each
bait, not including the excluded dots. This gave the aver-
age of the log-ratio of the sample (Cy3) to the standard
pool (Cy5), hereafter referred to as the values.
We first performed a normalization in which the median
value for each array was subtracted from all the values for
that sample. Some antibodies displayed biases in favor of
either the Cy3 or Cy5 channel, or showed large differences
between groups. Consequently, we selected a subset of 48
antibodies that did not have large differences between
groups, and had small within-group standard deviations
in order to perform a normalization that would be less
affected by antibodies with variable data or channel
biases. We computed the average of the raw values for
each antibody using the 80 arrays, and normalized the
individual slides to this standard. For each slide, the
median of the 48 differences for the array minus the cor-
responding values on the standard was subtracted from
the array, subtraction being used rather than division
because the values were already log-transformed. The
averaged raw and normalized data are available as supple-
mental information [22].
Western blot analysis
We used Western blots to analyze the level of C-reactive
protein (CRP) and serum-amyloid A (SAA) in sera of eight
selected lung cancer patients and eight healthy controls.
Subsequently, in order to validate our findings, we also
analyzed the CRP and SAA levels in an independent set of
30 additional lung cancer patients and 30 additional
healthy controls. Briefly, 5 µl of serum (from each patient)
was resolved by 15% SDS-PAGE, and then transferred to a
PVDF membrane. Following incubation in blocking
buffer (PBST0.1 containing 2% nonfat dry milk (Bio-
Rad)) for 2 h, the membrane was hybridized in blocking
buffer containing either anti-CRP or anti-SAA mouse
monoclonal antibodies at 0.5 µg/ml and 0.25 µg/ml for 1BMC Cancer 2005, 5:110 http://www.biomedcentral.com/1471-2407/5/110
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h. The membrane was then washed and incubated with a
horseradish peroxidase-conjugated sheep anti-mouse IgG
(Amersham) at a 1:1000 dilution for 1 h. After washing,
the membrane was briefly incubated in ECL (Enhanced
Chemiluminescence, Amersham), then exposed to imag-
ing film (Amersham). Integrated intensity measurements
were made of the respective bands and the measurements
were further analyzed statistically.
Results
Using microarrays containing 84 antibodies printed in
triplicate on slides, we measured the amount of target pro-
tein bound from 80 individual sera, with each sample
being compared to a pooled reference sample (consisting
of a mixture of all of the sera) in a two-color assay. Figure
1 shows a representative image of antibody arrays from
one slide. Eighty arrays with 24 sera from lung cancer
patients, 24 normal sera, or 32 sera from patients with
COPD were analyzed. The values determined were the
normalized average of base-2 logarithms of the intensity
arising from the individual sample divided by the inten-
sity arising from the pooled sample, which was measured
as Cy3 and Cy5 fluorescence, respectively. Values from
triplicate antibody dots from the same array were quite
reproducible, with average standard deviations of 0.14,
corresponding to approximately 10% variation in the
ratios.
Figure 2 depicts the first three principal components
obtained using all 84 antibodies. While lung cancer
patients were largely separated from the other two groups
of patients, there was no clear separation between COPD
and normal. This completely unsupervised view of the
data indicates that the distinction between lung tumor
patients' sera and the two other groups of sera was likely
the largest source of variation in the data set (Figure 2A).
The somewhat outlying samples were not associated with
a particular microarray slide (Figure 2B) or brightness of
the signals for either fluorescence. The first principal com-
ponent was most highly correlated with C-reactive protein
(CRP) and serum amyloid A (SAA).
In order to determine which antibodies distinguished sera
of lung tumor patients from the other sera, we fit a 1-way
analysis of variance model to the three groups of samples.
Cancer patient sera gave significantly different mean val-
ues for 7/84 antibodies when compared to normal sera,
and for 8/84 of the antibodies when compared to the
COPD sera (both at p < 0.01). The 7 antibodies that
yielded differences in the abundance of their correspond-
ing proteins between tumor and normal sera were com-
mon to the group of 8 antibodies that yielded differences
in the abundance of their corresponding proteins between
tumor and COPD sera. The additional protein identified
by the COPD comparison is troponin 1. We found
increased levels of CRP, SAA, α-1-antitrypsin (AAT) by
two distinct antibodies, and MUC1, and decreased levels
of transferrin and gelsolin, in lung cancer sera (Table 1).
Results obtained for the entire set of antibodies are avail-
able as supplemental data [22]. To assess the significance
of these findings, we randomly permutated the sample
labels 1000 times and performed the identical analysis on
each resulting data set. On average this yielded only 0.1
antibodies for which the tumor samples were increased or
decreased (at p < 0.1) compared to both other groups,
with 1 or more significant antibody found in only 8.1% of
the permuted data sets. Therefore, it is very unlikely that
the occurrence of differences in levels of proteins for the 7
antibodies observed in the actual data is due to chance.
The correlation within the group of lung cancer patients
between the CRP, SAA, AAT, MUC1, transferrin and gelso-
lin data values are summarized in Table 2, and the two-
dimensional log-scale plots for CRP and MUC1, and SAA
and AAT are shown in Figure 3. The expression levels of
CRP, SAA and AAT but not MUC1 were correlated with
each other (r > 0.4, p < 0.05). The two AAT measurements,
each derived from a different antibody, were significantly
correlated (r = 0.72, p < 0.001).
We performed a leave-one-out validation of a Diagonal
Linear Discriminant Analysis (DLDA) classifier that dis-
criminates tumor vs. non-tumor samples [23]. We left out
one sample at a time, then used the remaining 79 samples
Scanned fluorescence image of an antibody microarray  detected by two-color RCA Figure 1
Scanned fluorescence image of an antibody microarray 
detected by two-color RCA. 96 baits including 84 antibodies 
were spotted onto microscope slides coated with nitrocellu-
lose. 12 identical arrays were printed on each of seven slides. 
Each antibody was printed in triplicate on each array in order 
to form an 18 by 16 array of dots. A test sample labeled with 
biotin and a pooled reference sample labeled with digoxi-
genin were co-incubated on the microarray, and bound pro-
teins from both samples were detected by RCA. The 
microarray was scanned for Cy3 fluorescence (from the test 
sample) and Cy5 fluorescence (from the reference sample).BMC Cancer 2005, 5:110 http://www.biomedcentral.com/1471-2407/5/110
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to select the 5 antibodies with values increased in tumor
patient samples according to the p-values for 2-sample T-
tests of tumor vs. non-tumor samples, and constructed the
resulting discriminant function based on the 79 samples.
When using all of the data CRP, SAA, MUC1, and 2 AAT
antibodies would be selected as the top antibodies, in that
order. The value of this function was then computed for
the left out sample. Figure 4 shows the resulting Receiver
Operating Characteristic (ROC) curve that was obtained.
The calculations were also repeated using only the best 3
antibodies. Using 5 antibodies, the correct classification
of all 56 of the non-tumor samples was associated with
the correct classification of 15 of 24 cancer patient sera.
We obtained the same result with a different classifier that
used majority voting among the 5 closest neighboring
samples, where the distances were computed after scaling
each antibody's values by the pooled estimate of the
standard deviation (in analogy to DLDA). Analogous
The first 3 principal components from normalized log-base-2 ratios of sample to reference pool intensities, using all 84  antibodies Figure 2
The first 3 principal components from normalized log-base-2 ratios of sample to reference pool intensities, using all 84 antibod-
ies. The full 3-dimensional figures that can be rotated are available in the supplementary materials. In A, normal, COPD and 
lung cancer patients are marked with yellow, blue and red, respectively. The first three principal components account for 43% 
of the variance. In B, seven slides are marked separately with blue, black, yellow, green, purple, brown and red.
Table 1: Results for 7 antibodies showing significant differences between both lung tumor patients vs. normal controls and lung tumor 
patients vs. COPD patients.
Fold difference in means P-values from 1-way ANOVA P-value from 2-sample 
T-test
Antibody Tumor / Normal Tumor / COPD Tumor vs. Normal Tumor vs. COPD Tumor vs. Others
CRP 13.6 13.0 1.1 × 10-9 2.2 × 10-10 4.1 × 10-12
SAA 1.99 2.15 1.8 × 10-7 1.7 × 10-9 2.5 × 10-10
MUC1 1.30 1.42 3.3 × 10-3 4.3 × 10-5 5.3 × 10-5
AAT (1) 1.34 1.35 9.1 × 10-4 3.1 × 10-4 7.9 × 10-5
AAT (2) 1.42 1.33 1.1 × 10-3 3.7 × 10-3 5.2 × 10-4
Transferrin 0.73 0.71 2.7 × 10-4 2.3 × 10-5 7.2 × 10-6
Gelsolin 0.77 0.77 5.8 × 10-3 4.7 × 10-3 1.4 × 10-3BMC Cancer 2005, 5:110 http://www.biomedcentral.com/1471-2407/5/110
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results from cross-validating this simpler classifier using
only the 3 best antibodies correctly classified 17 of 24 can-
cer patient sera, while misclassifiying 4 of 56 non-tumor
samples, which also corresponds approximately to a point
on the ROC curve for the DLDA classifier when it used 3
antibodies. This illustrates that the results obtained with
DLDA classifiers were not particularly better than could be
obtained with other simple methods.
Table 2: Correlation between CRP, SAA, AAT, MUC1, and Transferrin protein expression in the serum of lung tumor patients.
SAA AAT (1) AAT (2) MUC1 Transferrin
r p value r p value r p value r p value r p value
CRP 0.60 0.0019 0.62 0.0012 0.61 0.0015 0.19 0.37 -0.175 0.41
SAA 0.48 0.019 0.41 0.049 -0.07 0.74 -0.121 0.57
AAT (1) 0.72 6.63 × 10-5 -0.02 0.94 0.012 0.96
AAT (2) 0.17 0.44 0.042 0.85
MUC1 0.226 0.29
Transferrin
Two-dimensional plots of normalized log-base-2 ratios of  sample to reference pool intensities for CRP and MUC1, and  SAA and AAT Figure 3
Two-dimensional plots of normalized log-base-2 ratios of 
sample to reference pool intensities for CRP and MUC1, and 
SAA and AAT.
Receiver Operating Characteristic (ROC) curves from leave- one-out validation of a Diagonal Linear Discriminant Analysis  classifier using the best 3 (or 5) antibodies Figure 4
Receiver Operating Characteristic (ROC) curves from leave-
one-out validation of a Diagonal Linear Discriminant Analysis 
classifier using the best 3 (or 5) antibodies. Both the antibod-
ies selected and the discriminant function were based solely 
on the remaining 79 samples.BMC Cancer 2005, 5:110 http://www.biomedcentral.com/1471-2407/5/110
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CRP and SAA were selected for Western blot analysis in
order to validate the specificity of antibody microarrays.
Eight lung cancer sera and 8 normal sera were resolved by
SDS-PAGE, then transferred to PVDF membranes. The
membranes were probed with anti-CRP or anti-SAA anti-
bodies. As shown in Figure 5, all of the sera from patients
with lung cancer showed much higher levels of CRP and
SAA compared to the sera from healthy controls. Subse-
quently, in order to validate our findings, we also ana-
lyzed the CRP and SAA levels in an independent set of 30
additional lung cancer patients and 30 additional healthy
controls. Integrated intensity measurements were made of
the respective bands and the measurements were further
analyzed statistically. The distribution of integrated inten-
sity measurement values obtained from the two groups of
samples for both assays are shown in Figure 6. The
number of tumor samples with values greater than the
largest value for normal samples was 17/30 for CRP (p =
3.1 × 10-7) and 13/30 for SAA (p = 2.3 × 10-5).
Discussion
Four proteins were found to be more abundant in the lung
cancer samples than those of the controls, namely CRP
(13.3 fold), SAA (2.0 fold), AAT (1.4 fold) and MUC1 (1.4
fold). There were no significant protein expression differ-
ences observed in serum between the various lung cancer
subtypes examined (adenocarcinoma, squamous and
small cell carcinomas: data not shown). The significant
increases in CRP and SAA protein levels found in the
serum of lung cancer patients by protein microarray were
confirmed by immunoassay. The increased levels of AAT
in lung cancer patient sera (1.4 fold) were observed using
two different antibodies, each obtained from a separate
source.
The pattern of increased abundances of CRP, SAA, AAT
and MUC1 in lung cancer patient sera that were observed
in our microarray-based study is concordant with previ-
ous studies of individual proteins. An increased C-reactive
protein level is part of the acute-phase response to most
forms of inflammation, infection, tissue damage, and
malignant neoplasia [25-27]. CRP [Uniprot PO2741]
forms homopentamers (pentaxins); it promotes phagocy-
tosis and complement fixation through calcium-depend-
ent binding (two per 23 kDa subunit) to
phosphorylcholine. CRP also interacts with DNA and his-
tones to scavenge nuclear material from damaged circulat-
ing cells. The expression of CRP is induced by IL-1 and IL-
6. While CRP itself is likely not useful as a single assay, it
may have clinical utility as part of a panel of diagnostic
biomarkers, especially in evaluating results from spiral CT
imaging [2]. CRP is mainly expressed in hepatocytes;
cytokines, especially interleukin-6, induce the expression
and release of CRP [28,29]. CRP has been suggested as a
useful prognostic indicator in esophageal carcinoma [30].
SDS-PAGE Western blot analysis of CRP and SAA Figure 5
SDS-PAGE Western blot analysis of CRP and SAA. CRP and 
SAA levels in sera of eight lung cancer patients and eight 
healthy controls were analyzed. The sera chosen were those 
that gave extremely high or low values for the corresponding 
assay on the antibody microarrays.
A scatter plot of integrated intensity measurements derived  from western blots of an independent set of sera from 30  additional lung cancer patients and 30 additional healthy con- trols, probed for SAA and CRP Figure 6
A scatter plot of integrated intensity measurements derived 
from western blots of an independent set of sera from 30 
additional lung cancer patients and 30 additional healthy con-
trols, probed for SAA and CRP. Values are base two loga-
rithms of the relative band intensities after adding 0.1 to each 
value (to force values to be greater than 0).BMC Cancer 2005, 5:110 http://www.biomedcentral.com/1471-2407/5/110
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Studies also showed that CRP was an independent deter-
minant of survival in non-small-cell lung cancer [31] and
could be useful in the initial evaluation of patients with
small cell lung cancer and in monitoring response to ther-
apy [32].
Serum amyloid A [Uniprot PO2735] is an acute-phase
protein that occurs in various isoforms in a molecular
mass range of 11–14 kDa. SAA is produced by hepatocytes
[33], secreted into serum and rapidly binds to high-den-
sity lipoprotein, with 90% occurring in the bound form
[34]. SAA occurs at low levels in sera of healthy individu-
als [35]. Patients with neoplastic disease, including lung
[36], renal [37], colorectal [38], prostate [39] and
nasopharyngeal cancers [40] exhibit a dramatic elevation
of serum SAA. However, SAA is not a cancer-specific
marker per se. Its elevation in serum has been reported
also in association with trauma, infection, inflammation,
rheumatoid arthritis, and amyloidosis [41]. A study of
621 subjects with cancer found substantial increases of
SAA levels in >95% (281 of 289) of patients with meta-
static solid tumors, all myelocytic leukemia patients and
all advanced lymphoma patients [42]. Interestingly, SAA
was not elevated in the group of 32 COPD patients
included in this study, suggesting a potential utility of SAA
in distinguishing between the two conditions possibly
due to a different cytokine profile between the two
groups.
α-1-antitrypsin [A1AT/SERPINA1, Uniprot PO1009] is a
secretory glycoprotein of molecular weight 44 kDa pro-
duced in the liver. It neutralizes the effects of proteases in
several organ systems, mainly in the lung. The major phys-
iological role of AAT in the lung is to bind and inhibit
elastase released from leucocytes in the lower respiratory
tract, thereby preventing the destruction of lung tissue
[43,44]. The normal range of serum or plasma AAT con-
centrations is 1200–2000 mg/L, with large increases in
inflammatory conditions, infections, cancer, liver disease,
or pregnancy [43]. It was previously reported that the
serum concentration of AAT increased with tumor growth
and could be utilized following tumor resection as an
indicator of relapse [45,46]. The prognostic significance of
AAT expression in lung adenocarcinomas has been evalu-
ated using immunohistochemistry [47]; strongly AAT-
positive cases had a worse prognosis than weak-to-moder-
ately AAT-positive or AAT-negative cases, suggesting that
increased AAT expression in lung adenocarcinoma
patients may be a prognostic indicator. The biological
basis for the association of acute-phase proteins, includ-
ing CRP, SAA, and AAT, with lung cancer remains largely
unknown. The correlation between CRP, SAA, and AAT
levels was significant (r > 0.4), likely reflecting a host
response. Significantly higher levels occur in patients with
metastatic disease compared to patients with limited dis-
ease [48].
We found serum MUC1 levels to be modestly elevated in
lung cancer compared to controls. MUC1 [P15941] is a
membrane-bound mucin of 122 kDa molecular weight
with several interacting isozymes, polymorphic tandem
repeats, and an extensively O-glycosylated core protein
[49]. In vitro studies suggested that MUC1 reduces E-cad-
herin-mediated cell-cell adhesion by steric hindrance,
which increases metastatic ability [50]. High MUC1 levels
also reduces the integrin-mediated cell adhesion to the
extracellular matrix [51]. The clinical importance of the
MUC1 glycoprotein, however, is not clear. Previous stud-
ies have reported that MUC1 was developmentally regu-
lated and aberrantly expressed by carcinomas, and a high
level of MUC1 mRNA expression in adenocarcinoma has
been associated with poor prognosis [52-58]. MUC1 was
also found to be up-regulated in non-small-cell lung can-
cer [59-61]. MUC1 is shed into the blood stream and thus
has a potential as a tumor marker, as demonstrated in
breast cancer [62-64]. Consistent with this finding, we
observed higher MUC1 expression levels in the sera of
lung cancer patients than in either healthy subjects or
patients with COPD. Additionally, MUC1 expression lev-
els did not show significant correlation with CRP, SAA, or
AAT, suggesting that the increased MUC1 levels might be
due to a different biological process. Interestingly, MUC1
serum levels in breast cancer patients were not concordant
with the levels observed in tumor tissues by
immunohistochemistry [64,65], so the increased serum
MUC1 expression may correspond to a specific isoform
expressed by cancer cells. Thus, expression levels of the
different MUC1 isoforms and their epitopes may need to
be evaluated to fully explain the increased levels in serum
of lung cancer patients.
Other acute-phase reactant serum proteins that have been
reported as significantly elevated in certain cancers were
not increased in this study of sera from lung cancer
patients. Most notably, the alpha sub-unit of haptoglobin
(MW 11.7 kDa) and isoforms of the haptoglobin-1
precursor (HAP1) have been reported to be increased in
serum of patients with ovarian and other gynecologic can-
cers [66,67].
Conclusion
Our results suggest that a distinctive serum protein profile
involving relatively abundant proteins may be observed
in cancer patients relative to healthy subjects or patients
with chronic disease. It is therefore likely that distinctive
mass peak profiles observed by mass spectrometry in can-
cer sera relative to control and that may be predictive of
outcome include a significant component related to host
response to tumors and acute phase reactants. The extentBMC Cancer 2005, 5:110 http://www.biomedcentral.com/1471-2407/5/110
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to which such indicators of host response have clinical
utility as a group, together with other tumor biomarkers
remains to be determined. The use of antibody microar-
rays directed against a broad range of serum and lung
tumor proteins would have utility for elucidating those
proteins with the greatest diagnostic utility.
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